What is Sonoma Pharmaceu's earnings per share (EPS)?

Sonoma Pharmaceu (SNOA) reported diluted earnings per share of $-2.79 for fiscal year 2025. This represents a 73.8% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Sonoma Pharmaceu Financials

SNOA

Source SEC Filings (10-K/10-Q) Updated Feb 10, 2026 Currency USD FYE March

This page shows Sonoma Pharmaceu (SNOA) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 32/100

Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores

Profitability

Sonoma Pharmaceu has an operating margin of -26.0%, meaning the company retains $-26 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is up from -36.9% the prior year.

Growth

Sonoma Pharmaceu's revenue grew 12.2% year-over-year to $14.3M, a solid pace of expansion. This earns a growth score of 54/100.

Leverage

Sonoma Pharmaceu has a moderate D/E ratio of 2.10. This balance of debt and equity financing earns a leverage score of 59/100.

Liquidity

Sonoma Pharmaceu's current ratio of 3.09 indicates adequate short-term liquidity, earning a score of 59/100. The company can meet its near-term obligations, though with limited headroom.

Cash Flow

While Sonoma Pharmaceu generated -$88K in operating cash flow, capex of $80K consumed most of it, leaving -$168K in free cash flow. This results in a low score of 22/100, reflecting heavy capital investment rather than weak cash generation.

Returns

Sonoma Pharmaceu generates a -78.4% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is up from -78.8% the prior year.

Piotroski F-Score Neutral

4/9

Sonoma Pharmaceu passes 4 of 9 financial strength tests. 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.

Earnings Quality Low Quality

0.03x

For every $1 of reported earnings, Sonoma Pharmaceu generates $0.03 in operating cash flow (-$88K OCF vs -$3.5M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$14.3M

YoY+12.2%

5Y CAGR-4.4%

10Y CAGR+0.3%

Sonoma Pharmaceu generated $14.3M in revenue in fiscal year 2025. This represents an increase of 12.2% from the prior year.

EBITDA

-$3.6M

YoY+21.1%

Sonoma Pharmaceu's EBITDA was -$3.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 21.1% from the prior year.

Net Income

-$3.5M

YoY+28.5%

Sonoma Pharmaceu reported -$3.5M in net income in fiscal year 2025. This represents an increase of 28.5% from the prior year.

EPS (Diluted)

$-2.79

YoY+73.8%

Sonoma Pharmaceu earned $-2.79 per diluted share (EPS) in fiscal year 2025. This represents an increase of 73.8% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$168K

YoY+93.0%

Sonoma Pharmaceu generated -$168K in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 93.0% from the prior year.

Cash & Debt

$5.4M

YoY+71.8%

5Y CAGR+7.8%

10Y CAGR-1.3%

Sonoma Pharmaceu held $5.4M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

YoY+109.4%

Sonoma Pharmaceu had 2M shares outstanding in fiscal year 2025. This represents an increase of 109.4% from the prior year.

Margins & Returns

Gross Margin

38.3%

YoY+1.0pp

5Y CAGR-7.1pp

10Y CAGR-14.4pp

Sonoma Pharmaceu's gross margin was 38.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 1.0 percentage points from the prior year.

Operating Margin

-26.0%

YoY+10.9pp

5Y CAGR+15.3pp

10Y CAGR+22.1pp

Sonoma Pharmaceu's operating margin was -26.0% in fiscal year 2025, reflecting core business profitability. This is up 10.9 percentage points from the prior year.

Net Margin

-24.2%

YoY+13.8pp

5Y CAGR-5.8pp

10Y CAGR+35.0pp

Sonoma Pharmaceu's net profit margin was -24.2% in fiscal year 2025, showing the share of revenue converted to profit. This is up 13.8 percentage points from the prior year.

Return on Equity

-78.4%

YoY+0.4pp

5Y CAGR-19.6pp

10Y CAGR-10.3pp

Sonoma Pharmaceu's ROE was -78.4% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 0.4 percentage points from the prior year.

Capital Allocation

R&D Spending

$1.8M

YoY-3.0%

5Y CAGR+6.3%

10Y CAGR+1.7%

Sonoma Pharmaceu invested $1.8M in research and development in fiscal year 2025. This represents a decrease of 3.0% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$80K

YoY+3900.0%

5Y CAGR-17.2%

10Y CAGR-5.4%

Sonoma Pharmaceu invested $80K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 3900.0% from the prior year.

SNOA Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$14.3M+12.2%	$12.7M-4.0%	$13.3M+5.1%	$12.6M-32.2%	$18.6M+3.9%	$17.9M
Cost of Revenue	$8.8M+10.4%	$8.0M-9.2%	$8.8M+1.9%	$8.6M-28.5%	$12.1M+23.1%	$9.8M
Gross Profit	$5.5M+15.2%	$4.7M+6.0%	$4.5M+12.1%	$4.0M-39.1%	$6.6M-19.2%	$8.1M
R&D Expenses	$1.8M-3.0%	$1.9M+803.9%	$207K+65.6%	$125K-77.5%	$555K-58.6%	$1.3M
SG&A Expenses	$7.4M-2.8%	$7.6M-14.3%	$8.8M-9.4%	$9.8M+3.2%	$9.5M-33.3%	$14.2M
Operating Income	-$3.7M+21.1%	-$4.7M-2.9%	-$4.6M+22.4%	-$5.9M-70.7%	-$3.4M+53.3%	-$7.4M
Interest Expense	N/A	N/A	$16K+260.0%	-$10K-183.3%	$12K-25.0%	$16K
Income Tax	$550K+380.6%	-$196K-493.9%	-$33K+90.1%	-$332K-146.6%	$713K+2358.6%	$29K
Net Income	-$3.5M+28.5%	-$4.8M+6.1%	-$5.2M-1.3%	-$5.1M-28.8%	-$4.0M-19.4%	-$3.3M
EPS (Diluted)	$-2.79+73.8%	$-10.63	$-1.52+20.8%	$-1.92	N/A	N/A

Metric	Q4'26	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25
Revenue	$4K-99.9%	$4.3M-22.4%	$5.6M+39.6%	$4.0M+7.0%	$3.8M+5.3%	$3.6M-0.4%	$3.6M+5.5%	$3.4M
Cost of Revenue	$3K-99.9%	$2.7M-22.5%	$3.5M+36.6%	$2.6M+14.6%	$2.2M-3.0%	$2.3M+3.4%	$2.2M+6.4%	$2.1M
Gross Profit	$2K-99.9%	$1.6M-22.2%	$2.1M+44.8%	$1.5M-4.2%	$1.5M+20.3%	$1.3M-6.7%	$1.4M+4.2%	$1.3M
R&D Expenses	$557-99.9%	$557K-3.1%	$575K-3.2%	$594K+44.5%	$411K-3.7%	$427K-15.6%	$506K+7.7%	$470K
SG&A Expenses	$2K-99.9%	$1.8M-5.9%	$1.9M-4.2%	$2.0M+10.8%	$1.8M-5.4%	$1.9M+9.9%	$1.7M-15.1%	$2.0M
Operating Income	$678+100.1%	-$678K-101.2%	-$337K+69.2%	-$1.1M-66.9%	-$656K+36.4%	-$1.0M-21.3%	-$850K+27.5%	-$1.2M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	$130+100.1%	-$130K+34.0%	-$197K-19600.0%	-$1K-100.4%	$248K+2655.6%	$9K-93.9%	$147K+0.7%	$146K
Net Income	$819+100.1%	-$819K-53.4%	-$534K+57.0%	-$1.2M-59.9%	-$776K+16.4%	-$928K-52.1%	-$610K+46.6%	-$1.1M
EPS (Diluted)	$0.48+200.0%	$-0.48-50.0%	$-0.32+57.9%	$-0.76	N/A	$-0.63-6.8%	$-0.59	$-1.34

SNOA Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$13.7M-7.1%	$14.7M-9.2%	$16.2M-13.9%	$18.8M+25.7%	$15.0M+2.9%	$14.6M
Current Assets	$12.6M+0.8%	$12.5M-9.1%	$13.8M-16.0%	$16.4M+26.6%	$13.0M+5.7%	$12.3M
Cash & Equivalents	$5.4M+71.8%	$3.1M-18.1%	$3.8M-48.4%	$7.4M+75.3%	$4.2M+14.3%	$3.7M
Inventory	$2.9M+7.2%	$2.7M-4.9%	$2.9M+7.3%	$2.7M+5.3%	$2.5M+16.0%	$2.2M
Accounts Receivable	$2.2M-23.0%	$2.9M+12.7%	$2.6M+6.9%	$2.4M-14.2%	$2.8M-29.4%	$4.0M
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$9.3M+7.9%	$8.6M+4.2%	$8.3M-18.7%	$10.1M+5.4%	$9.6M+7.7%	$8.9M
Current Liabilities	$4.1M+10.1%	$3.7M+0.1%	$3.7M-36.1%	$5.8M+42.7%	$4.1M-13.8%	$4.7M
Long-Term Debt	N/A	N/A	N/A	$0-100.0%	$1.3M	$0
Total Equity	$4.4M-28.1%	$6.1M-23.1%	$8.0M-8.3%	$8.7M+62.2%	$5.4M-4.6%	$5.6M
Retained Earnings	-$197.8M-1.8%	-$194.3M-2.6%	-$189.5M-2.8%	-$184.4M-2.8%	-$179.3M-2.3%	-$175.3M

Metric	Q4'26	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25
Total Assets	$14K-99.9%	$13.6M-1.7%	$13.9M-5.1%	$14.6M+6.6%	$13.7M+0.2%	$13.7M-0.1%	$13.7M+0.1%	$13.7M
Current Assets	$12K-99.9%	$12.1M-2.8%	$12.5M-4.6%	$13.1M+3.6%	$12.6M+2.2%	$12.4M+1.3%	$12.2M+2.5%	$11.9M
Cash & Equivalents	$3K-99.9%	$2.6M-15.6%	$3.0M-15.8%	$3.6M-32.9%	$5.4M+2.6%	$5.2M+28.4%	$4.1M+57.5%	$2.6M
Inventory	$4K-99.9%	$3.7M+1.9%	$3.6M-4.4%	$3.8M+30.4%	$2.9M-7.3%	$3.1M+10.8%	$2.8M+6.7%	$2.7M
Accounts Receivable	$2K-99.9%	$2.4M-11.9%	$2.7M+3.9%	$2.6M+16.6%	$2.2M-7.2%	$2.4M-23.8%	$3.2M-2.8%	$3.2M
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$10K-99.9%	$10.2M+1.2%	$10.1M-4.5%	$10.5M+13.5%	$9.3M+5.5%	$8.8M+5.6%	$8.3M-4.2%	$8.7M
Current Liabilities	$4K-99.9%	$4.2M-2.4%	$4.3M-10.8%	$4.8M+18.4%	$4.1M+10.6%	$3.7M+11.9%	$3.3M-11.8%	$3.8M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$3K-99.9%	$3.4M-9.4%	$3.8M-6.6%	$4.1M-8.0%	$4.4M-9.4%	$4.9M-9.0%	$5.4M+7.6%	$5.0M
Retained Earnings	$200K+100.1%	-$200.4M-0.4%	-$199.6M-0.3%	-$199.0M-0.6%	-$197.8M-0.4%	-$197.0M-0.5%	-$196.1M-0.3%	-$195.5M

SNOA Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$88K+96.3%	-$2.4M+61.0%	-$6.2M-44.8%	-$4.2M-25.8%	-$3.4M+26.4%	-$4.6M
Capital Expenditures	$80K+3900.0%	$2K-99.3%	$269K+96.4%	$137K-23.5%	$179K-13.1%	$206K
Free Cash Flow	-$168K+93.0%	-$2.4M+62.6%	-$6.4M-46.4%	-$4.4M-23.3%	-$3.6M+25.8%	-$4.8M
Investing Cash Flow	-$80K-3900.0%	-$2K+99.2%	-$258K-160.6%	-$99K-125.5%	$388K-89.4%	$3.6M
Financing Cash Flow	$3.0M+80.8%	$1.7M-32.7%	$2.5M-66.3%	$7.4M+123.6%	$3.3M+221.5%	$1.0M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q4'26	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25
Operating Cash Flow	$3K+100.4%	-$764K-20.3%	-$635K+68.5%	-$2.0M-2021.1%	-$95K-116.8%	$565K+59.6%	$354K+138.8%	-$912K
Capital Expenditures	$163-99.7%	$47K+370.0%	$10K-90.6%	$106K+125.5%	$47K+2250.0%	$2K-92.3%	$26K+420.0%	$5K
Free Cash Flow	$3K+100.4%	-$811K-25.7%	-$645K+69.6%	-$2.1M-1393.7%	-$142K-125.2%	$563K+71.6%	$328K+135.8%	-$917K
Investing Cash Flow	$163+100.3%	-$47K-370.0%	-$10K+90.6%	-$106K-125.5%	-$47K-2250.0%	-$2K+92.3%	-$26K-420.0%	-$5K
Financing Cash Flow	$90-100.0%	$210K+438.7%	-$62K-6.9%	-$58K-124.0%	$242K-65.8%	$708K-51.0%	$1.4M+127.0%	$636K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

SNOA Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	38.3%+1.0pp	37.3%+3.5pp	33.7%+2.1pp	31.6%-3.6pp	35.2%-10.1pp	45.3%
Operating Margin	-26.0%+10.9pp	-36.9%-2.5pp	-34.4%+12.2pp	-46.6%-28.1pp	-18.5%+22.7pp	-41.2%
Net Margin	-24.2%+13.8pp	-38.0%+0.8pp	-38.8%+1.5pp	-40.3%-19.1pp	-21.2%-2.7pp	-18.4%
Return on Equity	-78.4%+0.4pp	-78.8%-14.2pp	-64.6%-6.1pp	-58.5%+15.2pp	-73.7%-14.8pp	-58.8%
Return on Assets	-25.3%+7.6pp	-32.8%-1.1pp	-31.7%-4.8pp	-27.0%-0.6pp	-26.4%-3.6pp	-22.7%
Current Ratio	3.09-0.3	3.37-0.3	3.71+0.9	2.82-0.4	3.18+0.6	2.60
Debt-to-Equity	2.10+0.7	1.40+0.4	1.03+1.0	0.00-0.2	0.24+0.2	0.00
FCF Margin	-1.2%+17.7pp	-18.9%+29.5pp	-48.4%-13.7pp	-34.7%-15.6pp	-19.1%+7.7pp	-26.8%

Metric	Q4'26	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25
Gross Margin	37.9%0.0pp	37.9%+0.1pp	37.8%+1.4pp	36.5%-4.2pp	40.7%+5.1pp	35.6%-2.4pp	38.0%-0.5pp	38.5%
Operating Margin	15.6%+31.2pp	-15.6%-9.6pp	-6.0%+21.3pp	-27.3%-9.8pp	-17.5%+11.5pp	-28.9%-5.2pp	-23.8%+10.8pp	-34.6%
Net Margin	18.8%+37.7pp	-18.8%-9.3pp	-9.5%+21.4pp	-30.9%-10.2pp	-20.7%+5.4pp	-26.0%-9.0pp	-17.0%+16.7pp	-33.7%
Return on Equity	23.9%+47.7pp	-23.9%-9.8pp	-14.1%+16.5pp	-30.6%-13.0pp	-17.6%+1.5pp	-19.1%-7.7pp	-11.4%+11.6pp	-23.0%
Return on Assets	6.0%+12.0pp	-6.0%-2.2pp	-3.9%+4.7pp	-8.5%-2.8pp	-5.7%+1.1pp	-6.8%-2.3pp	-4.5%+3.9pp	-8.4%
Current Ratio	2.880.0	2.88-0.0	2.89+0.2	2.70-0.4	3.09-0.3	3.34-0.4	3.69+0.5	3.18
Debt-to-Equity	2.970.0	2.97+0.3	2.66+0.1	2.60+0.5	2.10+0.3	1.81+0.2	1.56-0.2	1.75
FCF Margin	74.8%+93.4pp	-18.6%-7.1pp	-11.5%+41.3pp	-52.8%-49.0pp	-3.8%-19.6pp	15.8%+6.6pp	9.2%+36.2pp	-27.0%

Similar Companies

Evoke Pharma Inc EVOK

$18.9M

Sunshine Biopharma Inc SBFM

$5.1M

Biofrontera Inc BFRI

$11.4M

Cbdmd Inc YCBD

$7.7M

Im Cannabis Corp IMCC

$2.0M

Frequently Asked Questions

What is Sonoma Pharmaceu's annual revenue?

Sonoma Pharmaceu (SNOA) reported $14.3M in total revenue for fiscal year 2025. This represents a 12.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Sonoma Pharmaceu's revenue growing?

Sonoma Pharmaceu (SNOA) revenue grew by 12.2% year-over-year, from $12.7M to $14.3M in fiscal year 2025.

Is Sonoma Pharmaceu profitable?

No, Sonoma Pharmaceu (SNOA) reported a net income of -$3.5M in fiscal year 2025, with a net profit margin of -24.2%.

What is Sonoma Pharmaceu's EBITDA?

Sonoma Pharmaceu (SNOA) had EBITDA of -$3.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Sonoma Pharmaceu's gross margin?

Sonoma Pharmaceu (SNOA) had a gross margin of 38.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Sonoma Pharmaceu's operating margin?

Sonoma Pharmaceu (SNOA) had an operating margin of -26.0% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Sonoma Pharmaceu's net profit margin?

Sonoma Pharmaceu (SNOA) had a net profit margin of -24.2% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Sonoma Pharmaceu's return on equity (ROE)?

Sonoma Pharmaceu (SNOA) has a return on equity of -78.4% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Sonoma Pharmaceu's free cash flow?

Sonoma Pharmaceu (SNOA) generated -$168K in free cash flow during fiscal year 2025. This represents a 93.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Sonoma Pharmaceu's operating cash flow?

Sonoma Pharmaceu (SNOA) generated -$88K in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Sonoma Pharmaceu's total assets?

Sonoma Pharmaceu (SNOA) had $13.7M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Sonoma Pharmaceu's capital expenditures?

Sonoma Pharmaceu (SNOA) invested $80K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Sonoma Pharmaceu spend on research and development?

Sonoma Pharmaceu (SNOA) invested $1.8M in research and development during fiscal year 2025.

How many shares does Sonoma Pharmaceu have outstanding?

Sonoma Pharmaceu (SNOA) had 2M shares outstanding as of fiscal year 2025.

What is Sonoma Pharmaceu's current ratio?

Sonoma Pharmaceu (SNOA) had a current ratio of 3.09 as of fiscal year 2025, which is generally considered healthy.

What is Sonoma Pharmaceu's debt-to-equity ratio?

Sonoma Pharmaceu (SNOA) had a debt-to-equity ratio of 2.10 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Sonoma Pharmaceu's return on assets (ROA)?

Sonoma Pharmaceu (SNOA) had a return on assets of -25.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Sonoma Pharmaceu's cash runway?

Based on fiscal year 2025 data, Sonoma Pharmaceu (SNOA) had $5.4M in cash against an annual operating cash burn of $88K. This gives an estimated cash runway of approximately 733 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Sonoma Pharmaceu's Piotroski F-Score?

Sonoma Pharmaceu (SNOA) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Sonoma Pharmaceu's earnings high quality?

Sonoma Pharmaceu (SNOA) has an earnings quality ratio of 0.03x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is Sonoma Pharmaceu?

Sonoma Pharmaceu (SNOA) scores 32 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.